Clinical Trials Logo

Substance Use Disorder clinical trials

View clinical trials related to Substance Use Disorder.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05448118 Withdrawn - Clinical trials for Substance Use Disorder

Virtual MOUD Treatment- Virtual POC Toxicology

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Care for Substance use disorders (SUD) such as Medication treatment of Opioid Use Disorder (MOUD) saves lives and is increasingly delivered virtually. Currently, 60% of VA outpatient addiction treatment occurs over video. However, toxicology testing, a major component of SUD care, currently requires in-person visits. A process for virtual point-of-care toxicology testing is needed. This research will develop a Virtual Point-of-Care Toxicology Testing Process for VA. This Pilot Trial will evaluate the feasibility, acceptability, and proximal effects of the process by evaluating provider and patient testing uptake, qualitative feedback, and health service use.

NCT ID: NCT05440721 Withdrawn - Tobacco Dependence Clinical Trials

Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.

NCT ID: NCT01207622 Withdrawn - Clinical trials for Attention Deficit Hyperactivity Disorder

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Start date: n/a
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to investigate the efficacy of Atomoxetine (ATMX) in the treatments of adolescent and young adult Attention Deficit Hyperactivity Disorder (ADHD) with comorbid Substance Use Disorder (SUD). The secondary objective of the study is to determine the efficacy of ATMX in preventing SUD relapse. As previous pre-clinical work has demonstrated that ATMX has led to significant improvement in ADHD in children and lacks abuse liability, the investigators hypothesize that ATMX will be efficacious in treating ADHD in adolescents and young adults with SUD, and that ATMX will also be efficacious in preventing SUD relapse.